CompletedNCT01271244
Effects of Escitalopram on Autonomic Reactivity in PTSD
A short description of this study’s research objective has not yet been verified.
Medication studyAges 19–55United States
Understand this study
Who was this study for?
This study was for people with PTSD. Listed age limits: 19 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Omaha, United StatesSee all locations and recruitment
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateJune 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 26
- Sponsor
- VA Nebraska Western Iowa Health Care System
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 19 Years to 55 Years
- Official registry ID
- NCT01271244
- Official title
- Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder Among Veterans of Operation Enduring Freedom and Iraqi Freedom (OEF/OIF)
Recruitment & locations
CompletedOmaha
Questions about this study
Who is behind this study?
The study sponsor is VA Nebraska Western Iowa Health Care System.
Did this study involve medication?
Yes. The study involved medication, including Escitalopram.
Who was this study for?
This study was for people with PTSD. Listed age limits: 19 years to 55 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01861847
7-Keto DHEA for PTSD
This study is completed. It focuses on PTSD and currently lists study information in the United States.
CompletedNCT03508700
TNX-102 SL 5.6 mg Taken Daily at Bedtime for PTSD
This study is completed in the United States. It is testing TNX-102 SL 5.6 mg Taken Daily at Bedtime for PTSD.
CompletedNCT00554177
A study for PTSD
This study is completed. It focuses on PTSD and currently lists study information in the United States.